Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Gillian A. Wallis is active.

Publication


Featured researches published by Gillian A. Wallis.


The Lancet | 2012

Identification of new susceptibility loci for osteoarthritis (arcOGEN): A genome-wide association study

Eleftheria Zeggini; Kalliope Panoutsopoulou; Lorraine Southam; N W Rayner; Aaron G. Day-Williams; M C Lopes; Vesna Boraska; T. Esko; Evangelos Evangelou; A Hoffman; Jeanine J. Houwing-Duistermaat; Thorvaldur Ingvarsson; Ingileif Jonsdottir; H Jonnson; Hanneke J. M. Kerkhof; Margreet Kloppenburg; S.D. Bos; Massimo Mangino; Sarah Metrustry; P E Slagboom; Gudmar Thorleifsson; Raine Eva.; Madhushika Ratnayake; M Ricketts; Claude Beazley; Hannah Blackburn; Suzannah Bumpstead; K S Elliott; Sarah Hunt; Simon Potter

Summary Background Osteoarthritis is the most common form of arthritis worldwide and is a major cause of pain and disability in elderly people. The health economic burden of osteoarthritis is increasing commensurate with obesity prevalence and longevity. Osteoarthritis has a strong genetic component but the success of previous genetic studies has been restricted due to insufficient sample sizes and phenotype heterogeneity. Methods We undertook a large genome-wide association study (GWAS) in 7410 unrelated and retrospectively and prospectively selected patients with severe osteoarthritis in the arcOGEN study, 80% of whom had undergone total joint replacement, and 11 009 unrelated controls from the UK. We replicated the most promising signals in an independent set of up to 7473 cases and 42 938 controls, from studies in Iceland, Estonia, the Netherlands, and the UK. All patients and controls were of European descent. Findings We identified five genome-wide significant loci (binomial test p≤5·0×10−8) for association with osteoarthritis and three loci just below this threshold. The strongest association was on chromosome 3 with rs6976 (odds ratio 1·12 [95% CI 1·08–1·16]; p=7·24×10−11), which is in perfect linkage disequilibrium with rs11177. This SNP encodes a missense polymorphism within the nucleostemin-encoding gene GNL3. Levels of nucleostemin were raised in chondrocytes from patients with osteoarthritis in functional studies. Other significant loci were on chromosome 9 close to ASTN2, chromosome 6 between FILIP1 and SENP6, chromosome 12 close to KLHDC5 and PTHLH, and in another region of chromosome 12 close to CHST11. One of the signals close to genome-wide significance was within the FTO gene, which is involved in regulation of bodyweight—a strong risk factor for osteoarthritis. All risk variants were common in frequency and exerted small effects. Interpretation Our findings provide insight into the genetics of arthritis and identify new pathways that might be amenable to future therapeutic intervention. Funding arcOGEN was funded by a special purpose grant from Arthritis Research UK.


Journal of Medical Genetics | 1991

Osteogenesis imperfecta: translation of mutation to phenotype.

Peter H. Byers; Gillian A. Wallis; Marcia C. Willing

By the end of the recently completed Fourth International Conference on Osteogenesis Imperfecta (Pavia, Italy, 9-12 September 1990) more than 70 mutations in the two genes that encode the chains of type I collagen, the major protein of bone, had been identified as the molecular cause of different forms of osteogenesis imperfecta (OI). Although by no means complete, the set of mutations in hand provides a rough guide to how to predict the phenotypic effects of mutations in type I collagen genes, predicts that certain classes of mutations will give rise to very mild phenotypes that will blend with common disorders, such as osteoporosis, and clarifies the genetic aspects of the widely used clinical classification of O.1


Arthritis & Rheumatism | 2009

Large‐scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand

Evangelos Evangelou; Kay Chapman; Ingrid Meulenbelt; Fotini B. Karassa; John Loughlin; Andrew Carr; Michael Doherty; Sally Doherty; Juan J. Gomez-Reino; Antonio Gonzalez; Bjarni V. Halldórsson; Valdimar B. Hauksson; Albert Hofman; Deborah J. Hart; Shiro Ikegawa; Thorvaldur Ingvarsson; Qing Jiang; Ingileif Jonsdottir; Helgi Jonsson; Hanneke J. M. Kerkhof; Margreet Kloppenburg; Nancy E. Lane; Jia Li; Rik Lories; Joyce B. J. van Meurs; Annu Näkki; Michael C. Nevitt; Julio Rodriguez-Lopez; Dongquan Shi; P. Eline Slagboom

OBJECTIVE GDF5 and FRZB have been proposed as genetic loci conferring susceptibility to osteoarthritis (OA); however, the results of several studies investigating the association of OA with the rs143383 polymorphism of the GDF5 gene or the rs7775 and rs288326 polymorphisms of the FRZB gene have been conflicting or inconclusive. To examine these associations, we performed a large-scale meta-analysis of individual-level data. METHODS Fourteen teams contributed data on polymorphisms and knee, hip, and hand OA. For rs143383, the total number of cases and controls, respectively, was 5,789 and 7,850 for hip OA, 5,085 and 8,135 for knee OA, and 4,040 and 4,792 for hand OA. For rs7775, the respective sample sizes were 4,352 and 10,843 for hip OA, 3,545 and 6,085 for knee OA, and 4,010 and 5,151 for hand OA, and for rs288326, they were 4,346 and 8,034 for hip OA, 3,595 and 6,106 for knee OA, and 3,982 and 5,152 for hand OA. For each individual study, sex-specific odds ratios (ORs) were calculated for each OA phenotype that had been investigated. The ORs for each phenotype were synthesized using both fixed-effects and random-effects models for allele-based effects, and also for haplotype effects for FRZB. RESULTS A significant random-effects summary OR for knee OA was demonstrated for rs143383 (1.15 [95% confidence interval 1.09-1.22]) (P=9.4x10(-7)), with no significant between-study heterogeneity. Estimates of effect sizes for hip and hand OA were similar, but a large between-study heterogeneity was observed, and statistical significance was borderline (for OA of the hip [P=0.016]) or absent (for OA of the hand [P=0.19]). Analyses for FRZB polymorphisms and haplotypes did not reveal any statistically significant signals, except for a borderline association of rs288326 with hip OA (P=0.019). CONCLUSION Evidence of an association between the GDF5 rs143383 polymorphism and OA is substantially strong, but the genetic effects are consistent across different populations only for knee OA. Findings of this collaborative analysis do not support the notion that FRZB rs7775 or rs288326 has any sizable genetic effect on OA phenotypes.


Annals of the Rheumatic Diseases | 2010

Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease

Jenny L. Scott; Christos Gabrielides; Rose K. Davidson; T.E. Swingler; Ian M. Clark; Gillian A. Wallis; Ray Boot-Handford; Thomas B. L. Kirkwood; Robert W Talyor; David Young

Background Oxidative stress is proposed as an important factor in osteoarthritis (OA). Objective To investigate the expression of the three superoxide dismutase (SOD) antioxidant enzymes in OA. Methods SOD expression was determined by real-time PCR and immunohistochemistry using human femoral head cartilage. SOD2 expression in Dunkin–Hartley guinea pig knee articular cartilage was determined by immunohistochemistry. The DNA methylation status of the SOD2 promoter was determined using bisulphite sequencing. RNA interference was used to determine the consequence of SOD2 depletion on the levels of reactive oxygen species (ROS) using MitoSOX and collagenases, matrix metalloproteinase 1 (MMP-1) and MMP-13, gene expression. Results All three SOD were abundantly expressed in human cartilage but were markedly downregulated in end-stage OA cartilage, especially SOD2. In the Dunkin–Hartley guinea pig spontaneous OA model, SOD2 expression was decreased in the medial tibial condyle cartilage before, and after, the development of OA-like lesions. The SOD2 promoter had significant DNA methylation alterations in OA cartilage. Depletion of SOD2 in chondrocytes increased ROS but decreased collagenase expression. Conclusion This is the first comprehensive expression profile of all SOD genes in cartilage and, importantly, using an animal model, it has been shown that a reduction in SOD2 is associated with the earliest stages of OA. A decrease in SOD2 was found to be associated with an increase in ROS but a reduction of collagenase gene expression, demonstrating the complexities of ROS function.


Annals of the Rheumatic Diseases | 2011

Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22

Evangelos Evangelou; Ana M. Valdes; Hanneke J. M. Kerkhof; Unnur Styrkarsdottir; Yanyan Zhu; Ingrid Meulenbelt; Rik Lories; Fotini B. Karassa; Przemko Tylzanowski; S.D. Bos; Toru Akune; N K Arden; Andrew Carr; Kay Chapman; L. Adrienne Cupples; Jin Dai; Panos Deloukas; Michael Doherty; Sally Doherty; Gunnar Engström; Antonio Gonzalez; Bjarni V. Halldórsson; Christina L. Hammond; Deborah J. Hart; Hafdis T. Helgadottir; Albert Hofman; Shiro Ikegawa; Thorvaldur Ingvarsson; Qing Jiang; Helgi Jonsson

Objectives Osteoarthritis (OA) is the most prevalent form of arthritis and accounts for substantial morbidity and disability, particularly in older people. It is characterised by changes in joint structure, including degeneration of the articular cartilage, and its aetiology is multifactorial with a strong postulated genetic component. Methods A meta-analysis was performed of four genome-wide association (GWA) studies of 2371 cases of knee OA and 35 909 controls in Caucasian populations. Replication of the top hits was attempted with data from 10 additional replication datasets. Results With a cumulative sample size of 6709 cases and 44 439 controls, one genome-wide significant locus was identified on chromosome 7q22 for knee OA (rs4730250, p=9.2×10−9), thereby confirming its role as a susceptibility locus for OA. Conclusion The associated signal is located within a large (500 kb) linkage disequilibrium block that contains six genes: PRKAR2B (protein kinase, cAMP-dependent, regulatory, type II, β), HPB1 (HMG-box transcription factor 1), COG5 (component of oligomeric golgi complex 5), GPR22 (G protein-coupled receptor 22), DUS4L (dihydrouridine synthase 4-like) and BCAP29 (B cell receptor-associated protein 29). Gene expression analyses of the (six) genes in primary cells derived from different joint tissues confirmed expression of all the genes in the joint environment.


Annals of the Rheumatic Diseases | 2011

Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study

Kalliope Panoutsopoulou; Lorraine Southam; Katherine S. Elliott; N Wrayner; Guangju Zhai; Claude Beazley; Gudmar Thorleifsson; N K Arden; Andrew Carr; Kay Chapman; Panos Deloukas; Michael Doherty; A. W. McCaskie; William Ollier; Stuart H. Ralston; Tim D. Spector; Ana M. Valdes; Gillian A. Wallis; J M Wilkinson; E Arden; K Battley; Hannah Blackburn; F.J. Blanco; Suzannah Bumpstead; L. A. Cupples; Aaron G. Day-Williams; K Dixon; Sally Doherty; Tonu Esko; Evangelos Evangelou

Objectives The genetic aetiology of osteoarthritis has not yet been elucidated. To enable a well-powered genome-wide association study (GWAS) for osteoarthritis, the authors have formed the arcOGEN Consortium, a UK-wide collaborative effort aiming to scan genome-wide over 7500 osteoarthritis cases in a two-stage genome-wide association scan. Here the authors report the findings of the stage 1 interim analysis. Methods The authors have performed a genome-wide association scan for knee and hip osteoarthritis in 3177 cases and 4894 population-based controls from the UK. Replication of promising signals was carried out in silico in five further scans (44 449 individuals), and de novo in 14 534 independent samples, all of European descent. Results None of the association signals the authors identified reach genome-wide levels of statistical significance, therefore stressing the need for corroboration in sample sets of a larger size. Application of analytical approaches to examine the allelic architecture of disease to the stage 1 genome-wide association scan data suggests that osteoarthritis is a highly polygenic disease with multiple risk variants conferring small effects. Conclusions Identifying loci conferring susceptibility to osteoarthritis will require large-scale sample sizes and well-defined phenotypes to minimise heterogeneity.


American Journal of Human Genetics | 2005

A Mutation in the Variable Repeat Region of the Aggrecan Gene (AGC1) Causes a Form of Spondyloepiphyseal Dysplasia Associated with Severe, Premature Osteoarthritis

Lindsay Gleghorn; Rajkumar Ramesar; Peter Beighton; Gillian A. Wallis

Spondyloepiphyseal dysplasia (SED) encompasses a heterogeneous group of disorders characterized by shortening of the trunk and limbs. The autosomal dominant SED type Kimberley (SEDK) is associated with premature degenerative arthropathy and has been previously mapped in a multigenerational family to a novel locus on 15q26.1. This locus contains the gene AGC1, which encodes aggrecan, the core protein of the most abundant proteoglycan of cartilage. We screened AGC1 for mutations and identified a single-base-pair insertion, within the variable repeat region of exon 12 in affected individuals from the family with SEDK, that introduces a frameshift of 212 amino acids, including 22 cysteine residues, followed by a premature stop codon. This is the first identification of an AGC1 mutation causing a human disorder. This finding extends the spectrum of mutated genes that may cause SED and thus will aid in the molecular delineation of this complex group of conditions.


Journal of Cell Biology | 2001

Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival

Bill Newman; Laure I. Gigout; Laure Sudre; Michael E. Grant; Gillian A. Wallis

Matrix Gla protein (MGP) is a 14-kD extracellular matrix protein of the mineral-binding Gla protein family. Studies of MGP-deficient mice suggest that MGP is an inhibitor of extracellular matrix calcification in arteries and the epiphyseal growth plate. In the mammalian growth plate, MGP is expressed by proliferative and late hypertrophic chondrocytes, but not by the intervening chondrocytes. To investigate the functional significance of this biphasic expression pattern, we used the ATDC5 mouse chondrogenic cell line. We found that after induction of the cell line with insulin, the differentiating chondrocytes express MGP in a stage-specific biphasic manner as in vivo. Treatment of the ATDC5 cultures with MGP antiserum during the proliferative phase leads to their apoptosis before maturation, whereas treatment during the hypertrophic phase has no effect on chondrocyte viability or mineralization. After stable transfection of ATDC5 cells with inducible sense or antisense MGP cDNA constructs, we found that overexpression of MGP in maturing chondrocytes and underexpression of MGP in proliferative and hypertrophic chondrocytes induced apoptosis. However, overexpression of MGP during the hypertrophic phase has no effect on chondrocyte viability, but it does reduce mineralization. This work suggests that coordinated levels of MGP are required for chondrocyte differentiation and matrix mineralization.


Journal of Medical Genetics | 1996

Mutations within the gene encoding the alpha 1 (X) chain of type X collagen (COL10A1) cause metaphyseal chondrodysplasia type Schmid but not several other forms of metaphyseal chondrodysplasia.

Gillian A. Wallis; B Rash; Bryan Sykes; J Bonaventure; P Maroteaux; Bernhard Zabel; R Wynne-Davies; Michael E. Grant; Ray Boot-Handford

Type X collagen is a homotrimer of alpha 1 (X) chains encoded by the COL10A1 gene. It is synthesised specifically and transiently by hypertrophic chondrocytes at sites of endochondral ossification. Point mutations and deletions in the region of the COL10A1 gene encoding the alpha 1 (X) carboxyl-terminal (NC1) domain have previously been identified in subjects with metaphyseal chondrodysplasia type Schmid (MCDS). To determine whether mutations in other regions of the gene caused MCDS or comparable phenotypes, we used PCR followed by SSCP to analyse the coding and promoter regions of the COL10A1 gene, as well as the intron/exon boundaries of five further subjects with MCDS, one subject with atypical MCDS, and nine subjects with other forms of metaphyseal chondrodysplasia. Using this approach, three of the subjects with MCDS were found to be heterozygous for the deletions 1864delACTT, 1956delT, and 2029delAC in the region of COL10A1 encoding the NC1 domain. These deletions would lead to alterations in the reading frame, premature stop codons, and the translation of truncated protein products. A fourth subject with MCDS was found to be heterozygous for a single base pair transition, T1894C, that would lead to the substitution of the amino acid residue serine at position 600 by proline within the NC1 domain. We did not, however, detect mutations in the coding and non-coding regions of COL10A1 in one subject with MCDS, the subject with atypical MCDS, and in the nine subjects with other forms of metaphyseal chondrodysplasia. We propose that the nature and distribution of mutations within the NC1 domain of COL10A1 causing MCDS argues against the hypothesis that the phenotype arises simply through haploinsufficiency but that an, as yet, unexplained mutation mechanism underlies this phenotype.


Arthritis & Rheumatism | 2014

Assessment of Osteoarthritis Candidate Genes in a Meta-Analysis of Nine Genome-Wide Association Studies

Manuel Calaza; Evangelos Evangelou; Ana M. Valdes; N K Arden; F.J. Blanco; Andrew Carr; Kay Chapman; Panos Deloukas; Michael Doherty; Tonu Esko; Carlos M. Garcés Aletá; Juan J. Gomez-Reino Carnota; Hafdis T. Helgadottir; Albert Hofman; Ingileif Jonsdottir; Hanneke J. M. Kerkhof; Margreet Kloppenburg; A. W. McCaskie; Evangelia E. Ntzani; William Ollier; Natividad Oreiro; Kalliope Panoutsopoulou; Stuart H. Ralston; Y.F. Ramos; José A. Riancho; Fernando Rivadeneira; P. Eline Slagboom; Unnur Styrkarsdottir; Unnur Thorsteinsdottir; Gudmar Thorleifsson

To assess candidate genes for association with osteoarthritis (OA) and identify promising genetic factors and, secondarily, to assess the candidate gene approach in OA.

Collaboration


Dive into the Gillian A. Wallis's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael E. Grant

Wellcome Trust Centre for Cell-Matrix Research

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kalliope Panoutsopoulou

Wellcome Trust Sanger Institute

View shared research outputs
Top Co-Authors

Avatar

Andrew Carr

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Panos Deloukas

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge